Ampio Pharmaceuticals, Inc. (AMPE): ANSOFF MATRIX [Dec-2025 Updated]

Look, with Ampio Pharmaceuticals, Inc. sitting at a market capitalization of just about $5.9K as of late 2025 and burning cash at a rate of -$8.63M TTM Net Income, the situation is stark. Honestly, you're not looking for incremental tweaks; you need a radical strategic pivot to survive. As your analyst, I've mapped out the four distinct paths-from safe market penetration to aggressive diversification-that Ampio Pharmaceuticals, Inc. must now consider to find a clear way forward, so check out the matrix below.

Ampio Pharmaceuticals, Inc. (AMPE) - Ansoff Matrix: Market Penetration

You're looking at Market Penetration for Ampio Pharmaceuticals, Inc. (AMPE) in a post-dissolution context, which means focusing on maximizing residual value from existing assets and aggressively managing the remaining financial structure.

Settle all remaining legal proceedings to eliminate contingent liabilities and preserve cash.

• The securities fraud class action and consolidated derivative actions reached a settlement in principle as of January 11, 2024.
• Investors received final approval for a $3 million deal resolving claims around February 21, 2025.
• The settlement resolved claims related to Ampion spanning December 29, 2020, and August 3, 2022.
• Stockholders approved the Plan of Dissolution on August 15, 2024, with dissolution effective August 16, 2024.

Maximize value from the discontinued Ampion intellectual property (IP) through a non-core asset sale.

Ampio Pharmaceuticals, Inc. informed the FDA it discontinued development of Ampion and withdrew 3 Investigational New Drug (IND) applications as of January 2023. Management made the decision starting in 2023 to significantly limit or discontinue much of the existing patent portfolio covering Ampion®. The company's market capitalization as of November 21, 2025, stood at $5.9K.

Re-analyze existing OA-201 preclinical data to identify a responsive OAK patient sub-population.

The efficacy results from recently completed nonclinical pre-IND enabling studies for OA-201 did not support an Investigational New Drug (IND) submission anticipated in early 2025. Previous smaller studies showed efficacy versus saline control to reduce pain and preserve cartilage in nonclinical models of osteoarthritis of the knee (OAK), but the pain reduction benefit was not observed in the data from the recent set of preclinical studies utilizing a larger population of animal subjects. Management stated the need to demonstrate a statistically significant improvement in both pain reduction and cartilage protection to support the IND.

Streamline operations further to reduce the annual cash burn from the reported -$8.63M TTM Net Income.

The company's management and Board were assessing internal and external options and taking immediate actions to preserve cash following the February 2024 OA-201 update. The goal is to reduce the annual cash burn from the reported trailing twelve months (TTM) Net Income of -$8.63M.

Secure a small, non-dilutive grant to fund a limited, highly focused nonclinical study on OA-201's cartilage protection.

The company is focused on preserving cash following the dissolution announcement. Securing external, non-dilutive funding remains a critical path to fund any limited, highly focused nonclinical study on OA-201's cartilage protection potential, as the company seeks to maximize value from this remaining asset.

Ampio Pharmaceuticals, Inc. (AMPE) - Ansoff Matrix: Market Development

You're looking at how Ampio Pharmaceuticals, Inc. could have expanded its market reach, even with a pipeline that faced significant hurdles. This is about taking existing technology or data into new therapeutic areas or geographies. For a pre-revenue stage biopharmaceutical company, this is where the highest potential upside often lies, but also where capital requirements spike.

The core small molecule formulation technology, which was the basis for the OA-201 program, was also explored for other indications beyond osteoarthritis of the knee (OAK). Ampio Pharmaceuticals, Inc. was dedicated to developing innovative proprietary drugs for critical therapeutic areas including eye disease and kidney disease, alongside inflammation and CNS disease.

Regarding the OA-201 asset, the plan to support an Investigational New Drug (IND) submission in early 2025 was ultimately not supported by efficacy results from larger nonclinical studies. Before this, the company had selected Ascendia Pharmaceuticals, Inc. in October 2023 to provide services culminating in cGMP manufacturing to support future Phase 1, 2 and 3 clinical trials for OA-201.

The inhalation biologic, AMP5A (inhaled Ampion), showed an excellent safety profile in its initial use. The Phase I study for COVID-19 respiratory distress enrolled 40 subjects, and there was a plan to increase the trial to 140 patients based on early positive data. The company noted in June 2022 that pursuing respiratory inflammation was not a near-term project or priority.

For the AR-300 formulation, which is a novel, proprietary small molecule formulation, preclinical data demonstrated promising anti-inflammatory properties in vitro and protection of cartilage in preclinical rat meniscal tear studies. The initial target for clinical development, if preclinical data were compelling, was osteoarthritis of the knee (OAK).

The historical safety data from the Ampion program was substantial. As of June 2022, Ampio Pharmaceuticals, Inc. had data in more than 1,500 Ampion-treated participants, along with a like number of saline-treated patients, which they were merging into a meta-analysis. This extensive dataset could have been presented to non-US regulators to support a compassionate use program for a new indication, leveraging the safety profile established across over 1,500 participants.

The operational reality was that the company had streamlined operations, expecting to save approximately $4.6 million annually, and by early 2023, staff was reduced to all but five employees, with a later count of 6 full-time employees listed in 2024. The company's strategic options assessment ultimately led to stockholders approving a Plan of Dissolution on August 15, 2024, with dissolution effective August 16, 2024.

Here's a quick look at the key assets and their last reported development status:

The pursuit of new markets, even with existing technology, requires capital. As of December 31, 2022, Ampio Pharmaceuticals, Inc. had $12.7 million in cash and cash equivalents, against net losses of $16.3 million in 2022.

• Apply small molecule technology to new indications like eye disease or kidney disease.
• Leverage preclinical data on AR-300 showing anti-inflammatory properties.
• Present Ampion safety data from over 1,500 patients to non-US regulators.
• Initiate low-cost proof-of-concept for AMP5A in a new respiratory indication (though deprioritized as of June 2022).

Ampio Pharmaceuticals, Inc. (AMPE) - Ansoff Matrix: Product Development

You're looking at the Product Development quadrant of the Ansoff Matrix for Ampio Pharmaceuticals, Inc. (AMPE), which means we are focused on taking new or modified offerings into existing markets, specifically Osteoarthritis of the Knee (OAK). Given the context that efficacy results from pre-IND enabling studies for OA-201 did not support an Investigational New Drug (IND) submission anticipated in early 2025, the path forward involves concrete financial and operational shifts.

Acquire or license a later-stage, de-risked asset specifically for the Osteoarthritis of the Knee (OAK) market.

This strategy pivots away from internal, higher-risk development. While specific acquisition/licensing deal values for 2025 are not public, the company's financial position as of March 15, 2024, showed a market capitalization of $1.85M and an EPS for the trailing 12 months of -$11.13. Following the February 2024 announcement regarding OA-201, management stated an intent to take immediate actions to preserve cash, which would dictate the size of any potential deal. The OAK market remains substantial, though specific 2025 market size figures for a licensable asset are not disclosed by Ampio Pharmaceuticals, Inc.

Develop a completely new, proprietary small molecule formulation (beyond OA-201/OA-20X) for OAK pain and function.

The company's pipeline snapshot from August 2025 indicated other New Molecular Entities (NMEs) in the pipeline, though not specifically for OAK beyond the OA-201 program. For instance, NCE-001 is listed in the Discovery phase for Alzheimer Disease, and AR-300 is listed in the Preclinical phase for Pain. The capital required for a completely new small molecule formulation development would need to be weighed against the reported cash position, which, at one point, was stated as S$5.32 Million in cash and cash equivalents, though the date for this figure is not current to the 2025 fiscal year. Developing a new NME requires significant capital outlay, far exceeding the $1.0 million decrease in clinical trial and sponsored research expense reported for the 2023 quarter compared to the 2022 quarter.

Partner with a Contract Development and Manufacturing Organization (CDMO) to optimize the OA-201 formulation for better efficacy.

Ampio Pharmaceuticals, Inc. has prior experience engaging with CDMOs. SEC filings from late 2023 noted expenses with a CDMO totaling $1.6 million, with expected increases into the first half of fiscal 2024. Re-engaging a CDMO for optimization would require a new budget allocation. The broader global pharmaceutical contract manufacturing and research services market size was calculated at USD 264.23 billion in 2025, indicating a robust external service sector available for partnership.

Focus all remaining R&D cash on a single, high-potential new molecular entity (NME) for OAK.

This is a capital preservation and focus move. The company's historical focus was on the OA-201 program, which was described as Ampio Pharmaceuticals, Inc.'s only product development opportunity as of February 2024. If a new, high-potential OAK NME were to be prioritized, the R&D cash available would be the primary constraint. The company had 18 full-time employees as of December 31, 2021, suggesting a lean internal R&D structure that relies heavily on external funding or partnerships.

Use the existing bioprocessing capability to offer contract services, generating a new revenue stream.

Generating revenue via contract services would be a direct counterpoint to the historical revenue of $76.8K as on Dec 31, 2014. Leveraging existing bioprocessing capability to enter the contract services market means competing in a sector projected to reach USD 495.52 billion by 2034. The manufacturing segment of this market accounted for approximately 64.64% of the share in 2024.

Financial and Operational Data Context

Strategic Focus Areas for Product Development

• Asset acquisition/licensing for OAK market.
• Development of NCE-001 (Alzheimer Disease) or AR-300 (Pain).
• Optimization of OA-201 formulation via CDMO partnership.
• Focusing R&D cash on a single, high-potential OAK NME.
• Generating revenue from contract bioprocessing services.

Finance: review the latest cash balance against the $1.6 million prior CDMO spend to model a potential new partnership budget by next Tuesday.

Ampio Pharmaceuticals, Inc. (AMPE) - Ansoff Matrix: Diversification

Execute a reverse merger with a private company that has a Phase 2 or Phase 3 asset in a completely different therapeutic area.

• AP-013 clinical trial status: Phase III
• AP-017 clinical trial status: Phase II

Divest the entire biopharmaceutical operation and become a shell company for a non-healthcare industry acquisition.

License the company's proprietary drug discovery platform to a larger pharmaceutical company for an upfront payment.

• 2023 Trailing Twelve Months (TTM) Pretax Income -$8.64 Million USD
• TTM Earnings (as of November 2025) N/A

Acquire a commercial-stage, non-biotech product line with immediate revenue to stabilize the balance sheet.

Restructure the company to focus on the CNS disease pipeline, a new market with new preclinical assets like NCE-001 for Alzheimer's.

• 2023 Net Income -$2.05M
• Reported EPS for Q1 2023 -0.26